Article Sidebar
Published:
Jul 9, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Cytotoxic activity of lithospermum erythrorhizon root extract against childhood acute leukemia cells via regulation of PI3K/AKT/mTOR pathway
Abstract
Purpose: To investigate the effect and mechanism of action of Lithospermum erythrorhizon root extract (LR) in childhood acute leukemia.
Methods: Human leukemic lymphoblast (CCRF-CEM cell line) cells were treated with LR (2, 4, and 8 mg/mL). Cell viability, cell apoptosis and cell cycle were measured using 3-(4,5-dimethylthiazol-2- thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) assay and flow cytometry, respectively. The levels of cell-cycle-related proteins including cyclin D1, cyclin E1, cyclin-dependent kinase 2 (CDK2), CDK4 and CDK6, as well as cleaved caspase 3, cleaved caspase 9 and Bcl-2-associated x (Bax). Also determined were B-cell lymphoma-2 (Bcl-2), E-cadherin, N-cadherin, vimentin, zonula occludens 1 (ZO-1), matrix metalloproteinase-2 (MMP-2) and MMP-9. Cell migration and invasion were assessed using scratch and Transwell assays. Finally, phosphoinositide 3-kinase (PI3K), phosphorylated serine/threonine kinase (pAKT), total AKT (t-AKT), mammalian target of rapamycin (mTOR), and phosphorylated mTOR (pmTOR) were measured using western blotting.
Results: Lithospermum erythrorhizon root extract not only dose-dependently inhibited cell viability, induced G1 phase accumulation, and downregulated CDK2, CDK4, CDK6, cyclin D1, and cyclin E1, but also elevated apoptosis, cleaved caspase 3, cleaved caspase 9, and Bax and decreased Bcl-2 expression levels. In addition, Lithospermum erythrorhizon root extract suppressed migration and invasion of CCRF-CEM cells, downregulated N-cadherin, vimentin, MMP-2, and MMP-9, and upregulated E-cadherin and ZO-1. Moreover, Lithospermum erythrorhizon root extracts dosedependently inhibited PI3K, p-AKT (ser473)/t-AKT, p-mTOR (ser2448)/mTOR, and p-mTOR (ser2481)/mTOR.
Conclusion: The findings provide a potential therapeutic approach to the treatment of childhood acute leukemia.
